The economic burden of elevated blood glucose levels in 2017 in the United States
Life Sciences The economic burden of elevated blood glucose levels in 2017 in the United States 26 September 2019 April Semilla Tim Dall Will...
April Semilla 's key focus areas include: supporting client investment decisions in pipeline assets, devices or new service offerings; health policy impact and health workforce and systems analysis; pharmaceutical market entry, pricing, reimbursement and value proposition strategic advisory services.
She previously supported the United States federal government agencies such as the Health Resources and Services Administration (HRSA) and the Centers for Disease Control and Prevention (CDC), the Ministry of Health in Zambia, health systems, associations, top 10 pharmaceutical and life sciences companies, and various Fortune 500 companies. She has also conducted commercial due diligence studies on municipal bond issue processes for advanced medical facilities and has expertise in creating bespoke health impact assessment models that report the impacts of environmental or policy changes on health outcomes.
Ms. Semilla holds a Master's Degree in Health Policy and Clinical Studies from Dartmouth College and is currently based in New York.